PIAS
NTLA icon

PCA Investment Advisory Services’s Intellia Therapeutics NTLA Stock Holding History

PCA Investment Advisory Services’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-100
Closed -$4.08K – 316
2023
Q2 		$4.08K Buy
+100
New +$4.05K ﹤0.01% 432

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

PCA Investment Advisory Services's NTLA Position: Q3 2023 in Review

PCA Investment Advisory Services sold out of Intellia Therapeutics (NTLA) in Q3 2023, closing a stake of 100 shares — an estimated $4.08K sold.

PCA Investment Advisory Services first reported a position in NTLA in Q2 2023 and held it in 1 quarter. The position peaked at $4.08K in Q2 2023. 284 funds tracked by Wall St. Rank hold NTLA as of Q3 2023.

  • PCA Investment Advisory Services reported no remaining Intellia Therapeutics position as of Q3 2023 after selling out during the quarter.
  • PCA Investment Advisory Services sold 100 Intellia Therapeutics shares in Q3 2023, an estimated $4.08K.
  • PCA Investment Advisory Services first reported a position in Intellia Therapeutics in Q2 2023 and held it in 1 quarter.
  • PCA Investment Advisory Services's Intellia Therapeutics position peaked at $4.08K in Q2 2023.
  • 284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2023.

Based on PCA Investment Advisory Services's 13F filing for Q3 2023, filed 13 Nov 2023.